Skip to main content

RELATIONSHIP BETWEEN NAEVI AND BASAL CELL CARCINOMA

Image result for RELATIONSHIP BETWEEN NAEVI AND BASAL CELL CARCINOMA

Source

Cancer and Population Studies Unit, Queensland Institute of Medical Research School of Life Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.

Abstract

BACKGROUND:

Melanoma and basal cell carcinoma (BCC) affect similar body sites and share a complex relationship with sun exposure.

OBJECTIVE:

To establish the existence and magnitude of the association between melanocytic naevi, the strongest predictors of melanoma, and BCC to give possible insights into shared pathways of solar ultraviolet tumourigenesis.

METHODS:

In a community-based longitudinal Australian study, detailed information was collected about sun sensitivity, and dermatologists assessed skin color and counted naevi on the forearms (1986) and back (1992). The BCC frequency and sites were prospectively monitored until 2007. Multivariate logistic regression was used to assess the association of naevi on the forearms or on the back with the development of BCC, adjusting for other risk factors.

RESULTS:

Of 1621 study participants in 1992, 1339 (average age 49) had complete follow-up and 401 (30%) of these had 1202 histologically confirmed BCCs until 2007. After adjustment for age, gender, skin color, naevi on the back and sun exposure, overall BCC risk increased significantly in those with forearm naevi (odds ratio: 1.5; 95% confidence intervals: 1.1-1.9). Risk of BCC specifically on the back was doubled in those with many (11 or more) forearm naevi compared with no forearm naevi (odds ratio: 2.4; 95% confidence interval: 1.1-4.8). Naevi on the back were not associated with subsequent basal cell carcinoma.

CONCLUSIONS:

High naevus prevalence on the arms is associated with future BCC development.

Comments

Post a Comment

Popular posts from this blog

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not specific for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter defibrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with defibrillators and affected pacemakers only when used in close proximity to the devi...
Post a Comment
Read more

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...
Post a Comment
Read more

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...
Post a Comment
Read more